Pennsylvania is currently home to 3293 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies
NCT06006546
Recruiting
This is a multicenter controlled interventional trial. This phase 1 trial is the first study to assess 426c.Mod.Core-C4b adjuvanted with 3M-052-AF + aluminum hydroxide suspension (Alum) in people living with HIV (PLWH).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/11/2024
Locations: Penn Prevention CRS, Philadelphia, Pennsylvania
Conditions: Chronic HIV Infection
Register for Updates
Music Listening: a Mechanistic Trial
NCT05541029
Recruiting
A randomized within-subject crossover trial to compare the effects of live and recorded music listening on biomarkers of stress and pain among children receiving mechanical ventilation in the pediatric intensive care unit.
Gender:
ALL
Ages:
Between 2 months and 17 years
Trial Updated:
12/11/2024
Locations: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Critical Illness
Register for Updates
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
NCT05388708
Recruiting
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatr... Read More
Gender:
ALL
Ages:
Between 14 days and 20 years
Trial Updated:
12/11/2024
Locations: Penn State Health Children's Hospital, Hershey, Pennsylvania
Conditions: Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Register for Updates
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
NCT04080804
Recruiting
The aim of this study is to potentiate adaptive immunity to enhance the anti-tumor activity of anti-PD1 antibody by the addition of anti-CTLA4 antibody or anti-LAG3 antibody (relatlimab) given in subjects with resectable locally advanced HNSCC prior to surgical resection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Register for Updates
Pilot Testing PICTURE-THIS
NCT06086301
Recruiting
This is a single-center pilot study examining the feasibility and acceptability of a transitional rehabilitation intervention, PICTURE-THIS, among critical illness survivors and their families. The intervention activities include transitional care coordination and activity-based rehabilitation delivered by a specialist team and integrated into usual care. There are three components to the assessment of feasibility and acceptability in this study: 1. User testing the PICTURE-THIS protocol to wor... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
12/10/2024
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Post-intensive Care Syndrome, Transitional Care, Critical Care, Health Services
Register for Updates
Testing the Effect of ENDS Flavors on Neurotransmission
NCT05836051
Recruiting
The overarching goal of this translational proposal is to determine if neuroactive flavor chemicals can enhance the addiction potential of electronic nicotine delivery systems (ENDS) by altering brain function and behavior.
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
12/10/2024
Locations: Penn State Health, Hershey, Pennsylvania
Conditions: Tobacco Dependence
Register for Updates
Adaptive Trial Scheduling in Naming Treatment for Aphasia
NCT05653466
Recruiting
Aphasia is a language disorder caused by stroke and other acquired brain injuries that affects over two million people in the United States and which interferes with life participation and quality of life. Anomia (i.e., word- finding difficulty) is a primary frustration for people with aphasia. Picture-based naming treatments for anomia are widely used in aphasia rehabilitation, but current treatment approaches do not address the long-term retention of naming abilities and do not focus on using... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: Language Rehab and Cognition Lab, Department of Communication Sciences and Disorders, School of Health and Rehabilitation Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Aphasia, Stroke
Register for Updates
Balancing Effortful and Errorless Learning in Naming Treatment for Aphasia
NCT05653440
Recruiting
Aphasia is a language disorder caused by stroke and other acquired brain injuries that affects over two million people in the United States and which interferes with life participation and quality of life. Anomia (i.e., word- finding difficulty) is a primary frustration for people with aphasia. Picture-based naming treatments for anomia are widely used in aphasia rehabilitation, but current treatment approaches do not address the long-term retention of naming abilities and do not focus on using... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: Language Rehab and Cognition Lab, Department of Communication Sciences and Disorders, School of Health and Rehabilitation Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Aphasia, Stroke
Register for Updates
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
NCT04743791
Recruiting
Single center, randomized, placebo- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: The University of Pittsburgh Asthma Institute at UPMC, Pittsburgh, Pennsylvania
Conditions: Asthma
Register for Updates
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and with Pembrolizumab
NCT04130516
Recruiting
This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and in combination with pembrolizumab. The study will include a dose escalation phase, a dose expansion phase, and phase 2A cohorts. Up to 200 patients will be accrued for this study. Up to 15 study sites in the United States will participate in the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Solid Tumor, Adult
Register for Updates
eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer
NCT05427240
Recruiting
This randomized non-inferiority study will use a 2x2 design where traditional standard-of-care pre-test (visit 1) and post-test (visit 2: disclosure) counseling delivered by a genetic counselor are replaced with a self-directed web-based eHealth intervention to provide critical data to inform optimal ways to deliver clinical genetic testing in eligible individuals, while maintaining quality of care and favorable cognitive, affective and behavioral outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Cancer
Register for Updates
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933
Recruiting
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
12/09/2024
Locations: Children's Hospital of Philadelphia- Center for Childhood Cancer Research, Philadelphia, Pennsylvania
Conditions: Colorectal Adenocarcinoma, Ewing Sarcoma
Register for Updates